ENYO Pharma raises €40 million in Series B fundraising

Published on 04/06/2018

Lyon, June 4, 2018 – ENYO Pharma, a clinical stage biotech company developing innovative drug candidates by mimicking virus strategies to modulate host cellular functions, today announced that it has completed a €40 million Series B round of financing from US and European investors. This new funding will enable the company to finance the two first Phase II clinical trial of its EYP001 asset in both chronic HBV and NASH. A second asset is also planned to enter clinic by 2019.

Read next in 'Press releases'

• ENYO Pharma announces the successful completion of phase Ib with its FXR agonist EYP001 and the start of phase II studies in two indications, NASH and HBV
• ENYO Pharma strengthens its leadership team with a NASH expert and announces that its Phase 1b trial in chronic HBV infected patients is on track with its FXR agonist EYP001
• ENYO Pharma opens a new subsidiary in Australia as a new managing center for clinical trials
• ENYO Pharma SA announces successful completion of EYP001 first in man Phase 1 study